x
Elara Pharmaceuticals Ltd - Logo
[contact-form-7 404 "Not Found"]

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • 666-888-0000
  • info@elarapharma.com
Elara Pharmaceuticals Ltd - Logo
  • info@elarapharma.com
  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News
    • In The News
    • Publications
  • Careers
Logo

Contact Info

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • +44 20 8040 0302
  • info@elarapharma.com
Alzheimer's

Sep2018

Artificial Intelligence enables first biomarker driven precision medicine therapy against Alzheimer

Elara Pharmaceuticals Ltd helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase 2a clinical trial. Tersan’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73. Professor Harald Hampel, M.D., Ph.D., presenting results at the AAIC […]

Read More
Cancer

Sep2018

Recombio and Elara Pharmaceuticals Ltd Identify Lung Cancer Patients Most Benefiting from Racotumomab Vaccine Therapy

Tersan has applied its advanced Artificial Intelligence platform KEM® and identified best responders to Racotumomab based on patients’ immune profile. Racotumab is a therapeutic vaccine developed by Recombio against non-small cell lung cancer (NSCLC), the most frequent type of lung cancers. Paris, Cambridge (MA) and Madrid– September 6, 2018 – Elara Pharmaceuticals Ltd (Paris, France and […]

Read More
Alzheimer's

Aug2018

Applying the cancer playbook to find treatment for Alzheimer’s disease

Applying the cancer playbook to find treatment for Alzheimer’s disease: see how Tersan’s KEM Artificial Intelligence platform is helping Anavex Life Sciences develop the first targeted therapy against Alzheimer’s disease.   “NEW YORK – July 25, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics […]

Read More
Autism

Jan2018

Autism and automatic analysis of hand movements

Kinematics could provide earlier and more specific information than clinicians on developmental problems in general, and those specific to Autism Spectrum Disorder in particular, a published study by Tersan and Necker Children Hospital finds. Developmental Trajectories of Hand Movements in Typical Infants and those at Risk of Developmental Disorders: An Observational Study of Kinematics during […]

Read More
Cancer

Jan2018

Tersan’s KEM® analysis shows positive impact on patient Quality of Life for ValiSeek VAL401 in Phase II trial for NSCLC patients

Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Elara Pharmaceuticals Ltd and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, […]

Read More
Cancer

Dec2017

Tersan®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients

London, Paris and Boston, 12 December 2017: Elara Pharmaceuticals Ltd and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Tersan’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 […]

Read More
Alzheimer's

Nov2017

CTAD 2017 (Boston, USA | 1-4 Nov)

Dr Mohammad Afshar (Tersan CEO) is presenting on the analysis of Phase 2a trial results using Tersan’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November. LB18 – Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease […]

Read More
Alzheimer's

Oct2017

Anavex incorporating Tersan’s KEM® AI platform in Alzheimer’s precision medicine approach

Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease PatientsANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed.Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success […]

Read More
Cancer

Jun2017

WIN 2017 (Paris | Jun 26-27)

Meet the Tersan team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. The conference program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ and is the place to be to learn about the latest in cancer research from leading practioners.

Read More
Cancer

May2017

Elara Pharmaceuticals Ltd finalist in EU eHealth 2017 with Onco KEM

Elara Pharmaceuticals Ltd were finalists in the Champions Category of the EU eHealth 2017 Competition with its clinical decision support system for oncologists, Onco KEM. Our solution: The right drug to the right patient with Onco KEM®, a novel decision support system helping oncologists to personalize cancer treatments according to the molecular profile of each patient. […]

Read More

Posts navigation

1 2 3 4 5 6

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Elara Pharmaceuticals Ltd, The AI DRUG Development Company

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • Call Us: +44 20 8040 0302
  • info@elarapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Elara Pharmaceuticals Ltd © 2024 All Rights Reserved